NCT04742595: SARS-CoV-2 Specific Cytotoxic T Lymphocytes for the Treatment of COVID-19 in Patients With Cancer

NCT04742595
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: COVID-19
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Early Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with existing lung metastasis
https://ClinicalTrials.gov/show/NCT04742595

Comments are closed.

Up ↑